Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers

다국어 초록 (Multilingual Abstract)

Knowledge about mRNA-1273 elicited T-cell response is limited. We investigated adverse reactions and interferon gamma release by specific T-cells among mRNA-1273 vaccinated health care workers. Seven to 13 weeks after complete vaccination low levels of specific Tcells were detected not correlating with antibody response. Severity of symptoms after first and number of symptoms after second immunization were associated with T-cell response.
Assessment of T-cell response in addition to antibody response is crucial because even few specific T-cells could add to protection against infection. Investigation of mRNA-1273 induced inflammatory processes might help improve reactogenicity and immunogenicity

참고문헌 (Reference)

1 Neidleman J, "mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status"

2 Rauch S, "mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection"

3 Meyer B, "Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test(sVNT)" 9 : 2394-2403, 2020

4 Verbeke R, "The dawn of mRNA vaccines : the COVID-19 case" 333 : 511-520, 2021

5 Angyal A, "T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers : a multicentre prospective cohort study" 2021

6 Pulendran B, "Systems biological assessment of human immunity to BNT162b2 mRNA vaccination"

7 Ivanova EN, "SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19"

8 Poland GA, "SARS-CoV-2 immunity : review and applications to phase 3 vaccine candidates" 396 : 1595-1606, 2020

9 Goel RR, "Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naive and recovered individuals following mRNA vaccination"

10 Cagigi A, "Immune responses induced by mRNA vaccination in mice, monkeys and humans" 9 : 61-, 2021

11 Van Praet JT, "Humoral and cellular immunogenicity of the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in nursing home residents" 73 : 2145-2147, 2021

12 Kruttgen A, "Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet" 287 : 113978-, 2021

13 Schwarz T, "Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany" 27 : 2174-2178, 2021

14 McMahan K, "Correlates of protection against SARS-CoV-2 in rhesus macaques" 590 : 630-634, 2021

15 Sahin U, "Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine"

16 Martinez-Gallo M, "Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides : a pilot study in health care workers"

17 Doria-Rose N, "Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19" 384 : 2259-2261, 2021

18 Jackson LA, "An mRNA vaccine against SARS-CoV-2 : preliminary report" 383 : 1920-1931, 2020